Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Osteoporosis Reports

Open Access 16-04-2024 | REVIEW

Regulatory Effect of Osteocytes on Extramedullary and Bone Marrow Adipose Tissue Development and Function

Authors: Beata Lecka-Czernik, Mohd Parvez Khan, Joshua Letson, Sudipta Baroi, Amit Chougule

Published in: Current Osteoporosis Reports

Login to get access

Abstract

Purpose of Review

This review summarizes evidence on osteocyte support of extramedullary and bone marrow adipocyte development and discusses the role of endogenous osteocyte activities of nuclear receptors peroxisome proliferator-activated receptor gamma (PPARG) and alpha (PPARA) in this support.

Recent Findings

PPARG and PPARA proteins, key regulators of glucose and fatty acid metabolism, are highly expressed in osteocytes. They play significant roles in the regulation of osteocyte secretome and osteocyte bioenergetics; both activities contributing to the levels of systemic energy metabolism in part through an effect on metabolic function of extramedullary and bone marrow adipocytes. The PPARs-controlled osteocyte endocrine/paracrine activities, including sclerostin expression, directly regulate adipocyte function, while the PPARs-controlled osteocyte fuel utilization and oxidative phosphorylation contribute to the skeletal demands for glucose and fatty acids, whose availability is under the control of adipocytes.

Summary

Bone is an inherent element of systemic energy metabolism with PPAR nuclear receptors regulating osteocyte-adipocyte metabolic axes.
Literature
1.
Buenzli PR, Sims NA. Quantifying the osteocyte network in the human skeleton. Bone. 2015;75:144–50.CrossRefPubMed
2.
Jansson JO, Palsdottir V, Hagg DA, Schele E, Dickson SL, Anesten F, et al. Body weight homeostat that regulates fat mass independently of leptin in rats and mice. Proc Natl Acad Sci U S A. 2018;115(2):427–32.CrossRefPubMed
3.
Jansson JO, Anesten F, Hagg D, Zlatkovic J, Dickson SL, Jansson PA, et al. The dual hypothesis of homeostatic body weight regulation, including gravity-dependent and leptin-dependent actions. Philos Trans R Soc Lond B Biol Sci. 1888;2023(378):20220219.
4.
•• Baroi S, Czernik PJ, Chougule A, Griffin PR, Lecka-Czernik B. PPARG in osteocytes controls sclerostin expression, bone mass, marrow adiposity and mediates TZD-induced bone loss. Bone. 2021;147: 115913. This study showed for the first time that sclerostin is under transcriptional control of PPARG.CrossRefPubMedPubMedCentral
5.
•• Kim SP, Seward AH, Garcia-Diaz J, Alekos N, Gould NR, Aja S, et al. Peroxisome proliferator activated receptor-gamma in osteoblasts controls bone formation and fat mass by regulating sclerostin expression. iScience. 2023;26(7):106999. This study linked sclerostin levels in circulation with "beiging" of extramedullary adipose tissue.CrossRefPubMedPubMedCentral
6.
•• Chougule A, Baroi S, Czernik PJ, Crowe E, Chang MR, Griffin PR, et al. Osteocytes contribute via nuclear receptor PPAR-alpha to maintenance of bone and systemic energy metabolism. Front Endocrinol (Lausanne). 2023;14:1145467. This study discovered PPARA as a regulator of osteocyte secretome supporting bone marrow adipogenesis and "beiging" of extramedullary adipose tissue.CrossRefPubMed
7.
• Brun J, Berthou F, Trajkovski M, Maechler P, Foti M, Bonnet N. Bone regulates browning and energy metabolism through mature osteoblast/osteocyte PPARgamma expression. Diabetes. 2017;66(10):2541–54. This is the first study indicating that PPARG in osteocytes regulates adipose tissue and systemic energy metabolism.CrossRefPubMed
8.
Sato M, Asada N, Kawano Y, Wakahashi K, Minagawa K, Kawano H, et al. Osteocytes regulate primary lymphoid organs and fat metabolism. Cell Metab. 2013;18(5):749–58.CrossRefPubMed
9.
Ukita M, Yamaguchi T, Ohata N, Tamura M. Sclerostin enhances adipocyte differentiation in 3T3-L1 cells. J Cell Biochem. 2016;117(6):1419–28.CrossRefPubMed
10.
Hong JH, Hwang ES, McManus MT, Amsterdam A, Tian Y, Kalmukova R, et al. TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science. 2005;309(5737):1074–8.CrossRefPubMed
11.
• Fairfield H, Falank C, Harris E, Demambro V, McDonald M, Pettitt JA, et al. The skeletal cell-derived molecule sclerostin drives bone marrow adipogenesis. J Cell Physiol. 2018;233(2):1156–67. This study provides in vitro and in vivo evidence for sclerostin role in support of bone marrow adipogenesis.CrossRefPubMed
12.
Kim SP, Frey JL, Li Z, Kushwaha P, Zoch ML, Tomlinson RE, et al. Sclerostin influences body composition by regulating catabolic and anabolic metabolism in adipocytes. Proc Natl Acad Sci U S A. 2017;114(52):E11238–47.CrossRefPubMedPubMedCentral
13.
Kim SP, Da H, Wang L, Taketo MM, Wan M, Riddle RC. Bone-derived sclerostin and Wnt/beta-catenin signaling regulate PDGFRalpha(+) adipoprogenitor cell differentiation. FASEB J. 2021;35(11): e21957.CrossRefPubMed
14.
Frey JL, Li Z, Ellis JM, Zhang Q, Farber CR, Aja S, et al. Wnt-Lrp5 signaling regulates fatty acid metabolism in the osteoblast. Mol Cell Biol. 2015;35(11):1979–91.CrossRefPubMedPubMedCentral
15.
Fulzele K, Lai F, Dedic C, Saini V, Uda Y, Shi C, et al. Osteocyte-secreted Wnt signaling inhibitor sclerostin contributes to beige adipogenesis in peripheral fat depots. J Bone Miner Res. 2017;32(2):373–84.CrossRefPubMed
16.
Chen M, Feng HZ, Gupta D, Kelleher J, Dickerson KE, Wang J, et al. G(s)alpha deficiency in skeletal muscle leads to reduced muscle mass, fiber-type switching, and glucose intolerance without insulin resistance or deficiency. Am J Physiol Cell Physiol. 2009;296(4):C930–40.CrossRefPubMedPubMedCentral
17.
Ma YH, Schwartz AV, Sigurdsson S, Hue TF, Lang TF, Harris TB, et al. Circulating sclerostin associated with vertebral bone marrow fat in older men but not women. J Clin Endocrinol Metab. 2014;99(12):E2584–90.CrossRefPubMedPubMedCentral
18.
Courtalin M, Bertheaume N, Badr S, During A, Lombardo D, Deken V, et al. Relationships between circulating sclerostin, bone marrow adiposity, other adipose deposits and lean mass in post-menopausal women. Int J Mol Sci. 2023;24(6):5922.
19.
Sheng Z, Tong D, Ou Y, Zhang H, Zhang Z, Li S, et al. Serum sclerostin levels were positively correlated with fat mass and bone mineral density in central south Chinese postmenopausal women. Clin Endocrinol (Oxf). 2012;76(6):797–801.CrossRefPubMed
20.
Urano T, Shiraki M, Ouchi Y, Inoue S. Association of circulating sclerostin levels with fat mass and metabolic disease–related markers in Japanese postmenopausal women. J Clin Endocrinol Metab. 2012;97(8):E1473–7.CrossRefPubMed
21.
Tozzi R, Masi D, Cipriani F, Contini S, Gangitano E, Spoltore ME, et al. Circulating SIRT1 and sclerostin correlates with bone status in young women with different degrees of adiposity. Nutrients. 2022;14(5):983.
22.
Stechschulte LA, Czernik PJ, Rotter ZC, Tausif FN, Corzo CA, Marciano DP, et al. PPARG post-translational modifications regulate bone formation and bone resorption. EBioMedicine. 2016;10:174–84.CrossRefPubMedPubMedCentral
23.
•• Baroi S, Czernik PJ, Khan MP, Letson J, Crowe E, Chougule A, et al. PPARG in osteocytes controls cell bioenergetics and systemic energy metabolism independently of sclerostin levels in circulation. bioRxiv. 2024. doi: https://​doi.​org/​10.​1101/​2024.​04.​04.​588029.​ This study showed that osteocyte bioenergetics under control of PPARG contribute significantly to the levels of systemic energy metabolism.
24.
25.
Farr JN, Xu M, Weivoda MM, Monroe DG, Fraser DG, Onken JL, et al. Targeting cellular senescence prevents age-related bone loss in mice. Nat Med. 2017;23(9):1072–9.CrossRefPubMedPubMedCentral
26.
Campisi J, Kapahi P, Lithgow GJ, Melov S, Newman JC, Verdin E. From discoveries in ageing research to therapeutics for healthy ageing. Nature. 2019;571(7764):183–92.CrossRefPubMedPubMedCentral
27.
Xu M, Pirtskhalava T, Farr JN, Weigand BM, Palmer AK, Weivoda MM, et al. Senolytics improve physical function and increase lifespan in old age. Nat Med. 2018;24(8):1246–56.CrossRefPubMedPubMedCentral
28.
Justesen J, Stenderup K, Ebbesen EN, Mosekilde L, Steiniche T, Kassem M. Adipocyte tissue volume in bone marrow is increased with aging and in patients with osteoporosis. Biogerontology. 2001;2(3):165–71.CrossRefPubMed
29.
Li Z, Hardij J, Bagchi DP, Scheller EL, MacDougald OA. Development, regulation, metabolism and function of bone marrow adipose tissues. Bone. 2018;110:134–40.CrossRefPubMedPubMedCentral
30.
Lecka-Czernik B, Rosen CJ, Kawai M. Skeletal aging and the adipocyte program: New insights from an “old” molecule. Cell Cycle. 2010;9(18):3648–54.CrossRefPubMedPubMedCentral
31.
Aaron N, Kraakman MJ, Zhou Q, Liu Q, Costa S, Yang J, et al. Adipsin promotes bone marrow adiposity by priming mesenchymal stem cells. Elife. 2021;10:e69209.
32.
Wiley CD, Sharma R, Davis SS, Lopez-Dominguez JA, Mitchell KP, Wiley S, et al. Oxylipin biosynthesis reinforces cellular senescence and allows detection of senolysis. Cell Metab. 2021;33(6):1124-36 e5.CrossRefPubMedPubMedCentral
33.
Liu X, Gu Y, Kumar S, Amin S, Guo Q, Wang J, et al. Oxylipin-PPARgamma-initiated adipocyte senescence propagates secondary senescence in the bone marrow. Cell Metab. 2023;35(4):667-84 e6.CrossRefPubMedPubMedCentral
34.
Wan S, Xie J, Liang Y, Yu X. Pathological roles of bone marrow adipocyte-derived monocyte chemotactic protein-1 in type 2 diabetic mice. Cell Death Discov. 2023;9(1):412.CrossRefPubMedPubMedCentral
35.
Suchacki KJ, Tavares AAS, Mattiucci D, Scheller EL, Papanastasiou G, Gray C, et al. Bone marrow adipose tissue is a unique adipose subtype with distinct roles in glucose homeostasis. Nat Commun. 2020;11(1):3097.CrossRefPubMedPubMedCentral
36.
Fidler IJ. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer. 2003;3(6):453–8.CrossRefPubMed
37.
Shin E, Koo JS. The role of adipokines and bone marrow adipocytes in breast cancer bone metastasis. Int J Mol Sci. 2020;21(14):4967.
38.
Salamanna F, Contartese D, Errani C, Sartori M, Borsari V, Giavaresi G. Role of bone marrow adipocytes in bone metastasis development and progression: a systematic review. Front Endocrinol (Lausanne). 2023;14:1207416.CrossRefPubMed
39.
Morris EV, Edwards CM. Bone marrow adipose tissue: a new player in cancer metastasis to bone. Front Endocrinol (Lausanne). 2016;7:90.CrossRefPubMed
40.
Hardaway AL, Herroon MK, Rajagurubandara E, Podgorski I. Marrow adipocyte-derived CXCL1 and CXCL2 contribute to osteolysis in metastatic prostate cancer. Clin Exp Metastasis. 2015;32(4):353–68.CrossRefPubMedPubMedCentral
41.
Diedrich JD, Rajagurubandara E, Herroon MK, Mahapatra G, Huttemann M, Podgorski I. Bone marrow adipocytes promote the Warburg phenotype in metastatic prostate tumors via HIF-1alpha activation. Oncotarget. 2016;7(40):64854–77.CrossRefPubMedPubMedCentral
42.
Templeton ZS, Lie WR, Wang W, Rosenberg-Hasson Y, Alluri RV, Tamaresis JS, et al. Breast cancer cell colonization of the human bone marrow adipose tissue niche. Neoplasia. 2015;17(12):849–61.CrossRefPubMedPubMedCentral
43.
Liu C, Zhao Q, Yu X. Bone marrow adipocytes, adipocytokines, and breast cancer cells: novel implications in bone metastasis of breast cancer. Front Oncol. 2020;10: 561595.CrossRefPubMedPubMedCentral
Metadata
Title
Regulatory Effect of Osteocytes on Extramedullary and Bone Marrow Adipose Tissue Development and Function
Authors
Beata Lecka-Czernik
Mohd Parvez Khan
Joshua Letson
Sudipta Baroi
Amit Chougule
Publication date
16-04-2024
Publisher
Springer US
Published in
Current Osteoporosis Reports
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI
https://doi.org/10.1007/s11914-024-00871-5